FDA Warns Oregon Company After CGMP Violations Found at Manufacturing Facility
FDA sent a warning letter to Ridge Properties, LLC, after inspectors found a variety of current good manufacturing practice violations at the company’s Salem, OR facility.
A warning letter, dated Oct. 13, 2017, details current good manufacturing practice (CGMP) violations found during an FDA inspection of the Salem, OR facility of Ridge Properties, LLC dba Pain Relief Naturally. The violations ranged from failure to test products for identity and strength to producing unapproved and misbranded drugs.
The FDA inspection was conducted from Feb. 28, 2017 to March 16, 2017. Investigators observed that the company was not performing appropriate laboratory testing on its products before distributing the products; products were not tested for chemical or microbial attributes.
The company also failed to establish an adequate quality control unit or quality procedures. “During the inspection, we found that your firm lacked critical procedures to ensure a functional quality unit including, but not limited to, procedures for establishing specifications and complaint handling,” the agency stated in the letter. The company also failed to separate areas to prevent contamination.
“Your firm manufactures drug products in a kitchen. You use household kitchen utensils and cookware, including a steel pot, (b)(4) blender, and kitchen spatula to mix ingredients. Our investigator observed conditions and practices that increase the risk of your drug products containing harmful and insanitary contaminants. For example, you had a window open to the outside for ventilation during production. You also stored cleaning equipment near formulation ingredients without adequate controls to prevent contamination,” the letter stated.
In addition, some of the products manufactured by the company were found by FDA to be either unapproved or misbranded. Products determined to be unapproved or misbranded drugs included Extra Strength Naturally HL Hemorrhoid Numbing With Lidocaine and Extra Strength PreTAT Gel With Added Lidocaine.
FDA recommended the company obtain a CGMP consultant to resolve the violations and stated: “Correct the violations cited in this letter promptly. Failure to promptly correct these violations may result in legal action without further notice including, without limitation, seizure and injunction. Unresolved violations in this warning letter may also prevent other Federal agencies from awarding contracts.”
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
